Literature DB >> 22320444

Functional outcomes of decompressive hemicraniectomy following malignant middle cerebral artery infarctions: a systematic review.

Alison McKenna1, Colin F Wilson, Sheena B Caldwell, David Curran.   

Abstract

Decompressive hemicraniectomy has been used increasingly in recent years to treat malignant middle cerebral artery territory infarction. This review examines functional outcome data, with the novel analysis of outcomes according to temporal periods post-surgery. Case series data were pooled to determine significant correlates of outcome. Severe disability was frequently the outcome among survivors within one month post-surgery. Time and rehabilitation were later reflected, with fewer deaths and the emergence of mild to moderate disability increasing in prevalence. Mortality and severe disability were consistently more probable with increasing age. Presurgical clinical status in the form of additional cerebral artery involvement and midline shift also correlated with mortality within the 30-day period post-stroke.

Entities:  

Mesh:

Year:  2012        PMID: 22320444     DOI: 10.3109/02688697.2012.654835

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  10 in total

1.  Impact of initial midline shift in glioblastoma on survival.

Authors:  Johannes Wach; Motaz Hamed; Patrick Schuss; Erdem Güresir; Ulrich Herrlinger; Hartmut Vatter; Matthias Schneider
Journal:  Neurosurg Rev       Date:  2020-06-04       Impact factor: 3.042

2.  Malignant cerebral edema after large anterior circulation infarction: a review.

Authors:  Allison E Arch; Kevin N Sheth
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-01

3.  Factors that Can Help Select the Timing for Decompressive Hemicraniectomy for Malignant MCA Stroke.

Authors:  Saadat Kamran; Abdul Salam; Naveed Akhtar; Ayman Alboudi; Kainat Kamran; Rajvir Singh; Numan Amir; Jihad Inshasi; Uwais Qidwai; Rayaz A Malik; Ashfaq Shuaib
Journal:  Transl Stroke Res       Date:  2018-03-06       Impact factor: 6.829

4.  Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia.

Authors:  Hannah X Chu; Hyun Ah Kim; Seyoung Lee; Jeffrey P Moore; Christopher T Chan; Antony Vinh; Mathias Gelderblom; Thiruma V Arumugam; Brad R S Broughton; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

Review 5.  Management of acute ischemic stroke.

Authors:  Alex Abou-Chebl
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

6.  DESTINY-S: attitudes of physicians toward disability and treatment in malignant MCA infarction.

Authors:  Hermann Neugebauer; Claire J Creutzfeldt; J Claude Hemphill; Peter U Heuschmann; Eric Jüttler
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

7.  A Cohort Study of Decompressive Craniectomy for Malignant Middle Cerebral Artery Infarction: A Real-World Experience in Clinical Practice.

Authors:  Zilong Hao; Xueli Chang; Hongqing Zhou; Sen Lin; Ming Liu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

8.  Revisiting Hemicraniectomy: Late Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Stroke and the Role of Infarct Growth Rate.

Authors:  Saadat Kamran; Naveed Akhtar; Abdul Salam; Ayman Alboudi; Kainat Kamran; Arsalan Ahmed; Rabia A Khan; Mohsin K Mirza; Jihad Inshasi; Ashfaq Shuaib
Journal:  Stroke Res Treat       Date:  2017-03-16

9.  Quantification of glioblastoma mass effect by lateral ventricle displacement.

Authors:  Tyler C Steed; Jeffrey M Treiber; Michael G Brandel; Kunal S Patel; Anders M Dale; Bob S Carter; Clark C Chen
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

10.  Strokectomy and Extensive Cisternal CSF Drain for Acute Management of Malignant Middle Cerebral Artery Infarction: Technical Note and Case Series.

Authors:  Fulvio Tartara; Elena Virginia Colombo; Daniele Bongetta; Giulia Pilloni; Carlo Bortolotti; Davide Boeris; Francesco Zenga; Alessia Giossi; Alfonso Ciccone; Maria Sessa; Marco Cenzato
Journal:  Front Neurol       Date:  2019-09-26       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.